Cu-67 can fully be supported by our BIOEMTECH gamma-eye as shown through a recent study conducted in our laboratories for preclinical research purposes. Following non-invasive in vivo imaging for 6 consecutive days, tumor targeting can be quantified, and the best time points can be concluded for further testing. A nice collaboration between BIOEMTECH laboratories and Oncodesign Services, on opening new routes to cutting-edge research.